Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216880 | 0.84 | JAK1 (0.43) | CNR1CNR2MAPK11MAPK14KMT2A | |
| SCHEMBL5215605 | 0.80 | KCNH2 (0.43) | MAPK11MAPK14 | |
| SCHEMBL5216121 | 0.80 | GPR119 (0.48) | GPR119STSCNR1CNR2MAPK11 | |
| SCHEMBL14519621 | 0.73 | MAPK11 (0.57) | GPR119MAPK11MAPK14CACNB4CACNA1A | |
| SCHEMBL14519634 | 0.73 | MAPK11 (0.55) | GPR119CNR1MAPK11MAPK14 | |
| SCHEMBL14519642 | 0.72 | MAPK11 (0.53) | GPR119STSMAPK11MAPK14 | |
| SCHEMBL14519640 | 0.71 | MAPK11 (0.52) | GPR119STSCNR1MAPK11MAPK14 | |
| SCHEMBL5312053 | 0.71 | MAPK11 (0.52) | GPR119STSMAPK11MAPK14MEN1 | |
| SCHEMBL5216217 | 0.71 | STS (0.43) | GPR119STSCNR1MEN1KMT2A | |
| SCHEMBL5259423 | 0.70 | MAPK11 (0.66) | GPR119STSMAPK11MAPK14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542680-B1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES AS TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1542680-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | disclosed |
| WO-2004022055-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, HMGB1 | GPR119 94/4885STS 2925/4885CNR1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.